ARCHIMED has invested in PlasmidFactory, a leading German firm specializing in plasmid and minicircle DNA production, to support its expansion and meet rising demand in gene therapy markets.

Information on the Target

ARCHIMED, a transatlantic private equity healthcare specialist, has made a significant investment in PlasmidFactory, located in Bielefeld, Germany. Established in 2000, PlasmidFactory stands as a leader in the contract manufacturing and service sector for plasmid and minicircle DNA. The company specializes in developing and producing high-quality plasmids and minicircles that are crucial for modifying cells and creating viral gene therapy vectors, such as AAV, LV, and mRNA. These vectors are instrumental in addressing various health challenges, including viral infections like COVID-19, and serious conditions such as cancer, cystic fibrosis, heart disease, diabetes, hemophilia, and AIDS, particularly in CAR-T cell therapy applications. Notably, plasmids have played a vital role in the production of mRNA COVID-19 vaccines.

Dr. Martin Schleef, the founder and CEO of PlasmidFactory, underscores the market demand for plasmids, stating, “Even with accelerated roll-outs, demand for plasmids is likely to vastly exceed supply for years to come.” The investment by ARCHIMED will serve as a catalyst for the rapid and efficient expansion of PlasmidFactory in a complex domain, with Dr. Schleef and his management team continuing to lead the company following the investment.

Industry Overview in Germany

The biopharmaceutical industry in Germany is one of the largest and most innovative sectors in Europe. National investment in biotechnology has surged, driven by a robust framework supporting research and development. Germ